Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
16th Nov 2006, 08:21 GMT
Diagnosoft recently secured FDA approval for their Diagnosoft HARP product, software that assists physicians in the analysis of magnetic resonance images by providing quantitative measurements and visualization of regional heart function.
Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology related news:
- Abbott's HUMIRA® Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients with Arthritis — Health News from Medical News Today
- Abbott's HUMIRA Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients With Psoriatic Arthritis — Government/ Industry Regulation News from StratCenter.com
- Viasys Gets FDA Approval on Sonara — FDA News News from StratCenter.com
- [Neuroscience] Structural and functional MRI reveals multiple retinal layers — Proceedings of the National Academy of Sciences recent issues
- FDA should return to 'science-based' agency — News-Medical News Feed
- FDA Allows Resumption of Lupus Trials with Epratuzumab — PR Newswire: All Releases
- FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria — PR Newswire: All Releases
- dbMotion Selected As Technology Platform for a Netherlands-based Health Information Network — Hospital Management
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting
- FermaVir's Founder and Board Member Professor Chris McGuigan receives the Royal Society of Chemistry's Award for Medicinal Chemistry